Visão geral da empresa
A health sciences company, Prenetics Global Limited focuses on advancing consumer health operations within Hong Kong, the United States, and international markets through the sale of wellness products under the IM8 brand and the provision of fulfillment services for sports nutrition goods under the E brand. The enterprise operates within the Healthcare sector, specifically targeting the Diagnostics & Research industry, a classification that positions the firm to leverage advancements in medical research methodologies and consumer health trends. Currently, the company possesses a market capitalization of $333.26M and generated annual revenue of $92.39M, while the specific employee count is listed as N/A in available records. These financial magnitudes suggest a mid-cap entity that has achieved significant scale in revenue generation, indicating a robust operational footprint capable of competing in both domestic and global wellness markets despite the absence of traditional earnings profitability metrics.
Saúde financeira
The company reported a revenue of $92.39M over the trailing twelve months, yet recorded a net income of $-52,696,000 and an EBITDA of $-32,973,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure or significant investment expenses. This negative free cash flow of $-60,990,500 indicates that the company is currently burning cash rather than generating liquidity, which constrains immediate financial flexibility and necessitates reliance on existing cash reserves for operational continuity. The gross margin stands at 53.0%, suggesting a favorable pricing power or high-value product mix, whereas the operating margin is negative at -33.3% and the profit margin is -63.1%, highlighting that overhead costs and other expenses are consuming more than half of the gross profits. On the balance sheet, the firm holds $73.35M in cash against a debt load of $1.77M, resulting in a debt-to-equity ratio of 1.01, which suggests a leveraged position where equity is only slightly larger than the total debt obligation. The current ratio of 3.01 demonstrates strong short-term liquidity, indicating that the company possesses ample current assets to cover its short-term liabilities without immediate distress. Furthermore, the return on equity is -31.8% and the return on assets is -11.0%, metrics that reveal that management is currently generating negative returns on the capital deployed, reflecting the challenges of scaling a business with significant net losses.
Avaliação de valorização
The valuation metrics present a complex picture with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is -29.04, implying that the market prices in future earnings recovery that has not yet materialized in trailing figures. The price-to-book ratio is 1.81, indicating that the market values the company at a premium of 81% over its book value, which could reflect expectations of future growth or intangible asset value not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 3.61 and an EV/EBITDA of -7.43 further underscore the disconnect between current sales performance and earnings power, suggesting the stock is priced based on revenue expansion potential rather than current profitability. The stock has experienced significant volatility, trading within a 52-week range bounded by a high of $23.63 and a low of $3.10, placing the current price dynamics in a wide band that reflects high investor sentiment swings. With a beta of 0.27, the stock exhibits low volatility relative to the broader market, moving less than half the magnitude of the market index, which provides a unique risk profile for portfolios seeking lower correlation with general market movements.
Growth & Income
Revenue growth accelerated dramatically with a year-over-year increase of 248.6%, whereas earnings growth is N/A due to the absence of positive net income, indicating that top-line expansion is occurring without corresponding profitability improvements. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, implying that retained earnings are being reinvested back into the business to fund growth initiatives or reduce the negative cash flow deficit. The combination of explosive revenue growth and negative earnings growth suggests a capital-intensive growth phase where the company prioritizes market share acquisition and product distribution over immediate profit generation. Overall, the growth and income profile is characterized by aggressive revenue expansion funded by cash reserves rather than organic earnings, with no current income distribution to complement the capital appreciation strategy.